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Immunologic Mechanisms of Parenchymal
Lung Injury
by William F. Willoughby* and Judith Barbaras Willoughby*
The lung, like most other organs, is susceptible to injury by circulating immune complexes, and also by
humoral autoantibody and immune lymphocytes which specifically recognize selected lung antigens. In
addition, by virtue ofits direct communication with the external environment, the lung can also be injured
by inhaled environmental agents which trigger inflammatory reactions mediated by immune effector
systems. Although major emphasis to date has been placed on the ability of inhaled antigens to first
sensitize, then provoke, immunologically specific reactions in the lung, there is increasing evidence to show
that these same immune effector systems are also triggered in an immunologically nonspecific fashion by a
certain environmental agents (termed "mitogens") which activate leukocytes in a polyclonal fashion. Such
agents include certain viruses and other microorganisms, bacterial endotoxin, a wide variety of plant
lectins, and certain chemicals, such as the phorbol esters. Although such agents act in an immunologically
nonspecific fashion, they are nonetheless quite specific from achemical viewpoint, and in many cases act by
binding to specific receptors on the cell surface. By activating macrophages directly, and by activating
much larger percentages of a given lymphocyte population than do specific antigens, they induce
correspondingly amplified inflammatory reactions in vivo. Recent studies with animal models indicate that
inhaled mitogens are strikingly effective in inducing pulmonary inflammation, whereas inhaled antigens
(lacking mitogenic activity) produce little if any parenchymal injury in immunized recipients, unless
administered in conjunction with a mitogen. Ongoing studies using such models promise to provide
valuable new insight into the biologic properties which govern the pathogenicity ofinhaled environmental
agents, the mediators they release, and the biochemical basis for variations in individual susceptibility to
injury by such agents.
Introduction
The association between inhalation of organic dusts
and the development of chronic pulmonary disease has
been recognized for centuries (1). However, whereas the
actions ofsuch dusts have traditionally been considered
to be a nonspecific "toxic" effect, advances in our
understanding of tissue inflammation have led to
revised, more detailed hypotheses concerning mecha-
nisms of tissue injury. Studies of environmental lung
disease have been particularly influenced by related
advancements in pulmonary immunology and immuno-
pathology, perhaps best exemplified by the delineation
of IgE-mediated allergic asthma (an airway disorder
which will not be discussed in this paper), and the
production ofpulmonary hemorrhage and acute glomer-
ulonephritis by antibasement membrane antibodies in
patients with Goodpasture's syndrome (2).
Currently, there is considerable interest in immuno-
logic mechanisms which may be responsible for environ-
mental lung diseases associated with dust inhalation.
Such studies were prompted largely by Pepys (3), who,
nearly two decades ago, demonstrated that sera from
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patients with farmer's lung contained precipitating
antibody against the causative agent, Micropolyspora
faeni. Subsequently, a number of environmental lung
diseases, characterized by the presence ofprecipitating
serum antibody against pathogenic dust antigens, have
been described (4). Pepys proposed that these pulmo-
nary diseases, which he termed "extrinsic allergic
alveolitis" have also been known as "hypersensitivity
pneumonitis," result from local formation ofpathogenic
immune complexes composed of inhaled antigen and
humoral antibody.
There are serious objections to such a straightfor-
ward immune complex hypothesis, however, as Pepys
himself noted (5). First, it has been well established
that many, if not most, individuals who inhale these
pathogenic dusts develop humoral antibodies to dust
antigens but fail to develop evidence of disease (6).
Second, there is little if any obvious relationship. be-
tweenthe magnitude or specificity ofindividual immune
responses to dust antigens and the extent ofpulmonary
disease (7). This is in contrast to the cutaneous Arthus
reaction and other immune complex-mediated phenom-
ena. Third, whereas virtually all dust antigens, when
inhaled, stimulate production of specific host antibody
(8, 9), only selected antigens (e.g., pigeon droppings)
appear to be pathogenic; other equally antigenic, osten-WILLOUGHBY AND WILLOUGHBY
sibly similar antigens (e.g., chicken droppings) seldom
if ever cause allergic alveolitis (5). Pepys (5) has thus
further proposed that immune complex injury occurs in
association with a more rapidly developing, immediate-
type hypersensitivity response which potentiates subse-
quent immune complex formation. Interestingly, how-
ever, Pepys (10) has noted that patients with allergic
alveolitis are notably nonatopic, and that these im-
mediate-type hypersensitivity reactions are not medi-
ated by IgE-class antibody.
Subsequently, several alternative hypotheses have
been proposed which, in essence, identify both cellular
and humoral mechanisms as the prime cause of lung
injury (7); such hypotheses have been based largely on
demonstrations ofcellular as well as humoral immunity
to dust antigens in patients with allergic alveolitis. As
with Pepys' original hypothesis, however, they fail to
account for the differential pathogenicity of various
dust antigens, and also the poor correlation between
test measurements ofhost immunity and the severity of
lung disease. In fact, many now believe that host
immunity to environmental dust antigens merelyreflects
a history of exposure.
Clinical dataalso suggestthatnoninfectious parenchy-
mal lung diseases other than allergic alveolitis may also
be immunologically mediated; both fibrosing alveolitis
(11) and Wegener's granulomatosis (12), for example,
have been ascribed to immune complex-type reactions.
Moreover, immune complexes have been identified in
the circulation of a variety of patients with active
interstitial pneumonitis (but not end-stage fibrosis),
including patients with "idiopathic" interstitial inflam-
mation, as well as in patients with other known immune
complex-mediated connective tissue disorders (13).
Yet a new dimension has been recently added to our
understanding of "immunologic" disorders, namely, the
recognition that both the cellular and humoral effector
systems can also be triggered through immunologically
nonspecific mechanisms, as, for example, the acute
respiratory distress syndrome caused by nonimmune
activation ofcomplement in patients undergoing extra-
corporeal dialysis (14). This paper will not attempt to
outline the entire spectrum of human lung diseases
thought to be immunologically mediated, nor will it
review in detail all known immune effector systems, but
rather it will concentrate on recent advances in our
understanding of how immune effector systems might
be activated in the lung. In particular, we will highlight
the potential role ofenvironmental and endogenous cell
activators, emphasizing the pathogenic consequences
associated with the release of certain inflammatory
mediators by activated lung cells.
Immune Effector Systems
Immunologic tissueinjuryismediatedthrough activa-
tion of one or more effector systems. Immunologic
specificity exists only during the recognition and bind-
ing of antigen to antigen-specific lymphocyte receptors
or immunoglobulin combining sites. Such initial reac-
tions are not of great pathological moment in them-
selves, but serve to trigger cellular and humoral effec-
tor systems (such as macrophages and complement,
respectively). These systems, through a process of
self-activation and self-amplification, generate soluble
inflammatory mediators, which recruit and activate
additional leukocytes. When fully developed, such a
process constitutes a true inflammatory nidus, recog-
nized clinically and histologically.
Although the activation of the immune effector sys-
tems in such instances is immunologically specific in
nature, the effector systems themselves function in an
immunologically nonspecific fashion. These effector/
amplification systems are, moreover, controlled and
regulated by discrete inhibitor systems, including beta-
adrenergic agonists, E-series prostaglandins and hista-
mine (15), and in the lung, surface-active materials as
well (16). Depending on the site and manner in which
effector systems are activated (and regulated), they
may serve either to protect the host or to cause tissue
injury and disease.
Immune effector systems comprise both humoral and
cellularelements, and attemptstocharacterize immuno-
logic disorders as being one or the other in nature
constitute an artificial distinction. For example, effector
mechanisms associated with "cellular" reactions (such
as the tuberculin skin reaction) are mediated in part by
soluble factors; indeed, certain "humoral" factors, such
as complement, are produced by activated monocytes
and macrophages (17). Traditionally, humoral immune
effector mechanisms have included the complement,
kinin and coagulation systems. The latter two systems
will not be considered further, and the reader is
referred to several excellent reviews which discuss
these areas in depth (18,19).
Complement
Activation ofthe complement systemis characterized
by the sequential proteolytic cleavage of complement
proteincomponents, therebyconvertinginactive precur-
sor forms into biologically active fragments (Fig. 1).
While the complement components are typically found
in the plasma, they can also be synthesized locally by
macrophages (17), indicatingthatcomplement-mediated
reactions could theoretically occurin the lungair spaces
in the absence ofother humoral constituents. However,
studies by Reynolds et al. (20) argue against such a
possibility by showingthatratios ofcomplement compo-
nents to serum albumin, as measured in human
bronchopulmonary lavage fluid, are lower than those in
serum. Among the biologic activities associated with
these fragments are: increases in vascular permeability
(C3a; C5a), contraction of smooth muscle (C3a; C5a),
enhanced phagocytosis (C3b;), leukocyte chemotaxis
(C5a) and cell lysis (C5b-9). These biologic activities are
in turn controlled not only through spontaneous decay,
where biologic activity decreases spontaneously with
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time, but also through the action of serum inhibitors,
such as the Cl-esterase inhibitor, C3b inactivator and
31H (21, 22). Absence of the Cl-esterase inhibitor is
associated with episodes oflaryngeal edema (hereditary
angioneurotic edema) (23), while the inability ofthe C3b
inactivator and f1H control protein to effectively regu-
late the formation ofthe alternative pathway C3-cleaving
enzyme, BbC3b (due either to a C3b inactivator defi-
ciency, ortothe bindingofan autoantibody to the C3bBb
complex), is associated with a hypocomplementemic
form of glomerulonephritis (24).
The complement cascade can be activated by two
major pathways. The "classical" pathway is initiated by
binding and-activation of the Clq,r,s assembly, leading
in turn to sequential activation of C4, C2, C3 and C5-9.
The "alternative" pathway bypasses the Cl, C4 and C2
steps, utilizing instead factors B and D plus properdin,
C3, and C5-9 (25). Immune complexes ofantibody and
antigen activate complement primarily via the classical
pathway. Both pathways can be activated, however, in
an immunologically nonspecific fashion by a variety of
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FIGURE 1. Schematic representation of the complement activation
pathways. In the classical pathway, as activated by antigen-antib-
odycomplexes, Clq is altered bybindingto the Fcimmunoglobulin
region, leading to successive activation of Clr and then Cls. Cls
enzymatically cleaves C4 and C2 to generate the C3-cleaving
enzyme, C4b,2a, which combines with C3b to form the C5-cleaving
enzyme, C4b,2a,3b. In the alternative pathway, assembly of the
C3-cleaving enzyme, PBb,C3b, begins with binding of nascent
C3b to a suitable activating surface (such as bacterial polysac-
charides), followed by binding ofFactor B, which is then activated
to Bb through enzymatic cleavage by Factor D. This C3-cleaving
complex, Bb,C3b, is stabilized bybinding ofproperdin (P) to a site
on C3b. A C5-cleaving enzyme is then formed by the uptake of a
second C3b to yield C3b,PBb,C3b. The small amount of nascent
C3b required to initiate this autocatalytic process is slowly
generated by the inefficient enzyme, Bb,C3, normally present in
blood, (or, alternatively, by C4b,2a from the classical pathway).
Two control proteins, 01H and C3b inactivator, however, effectively
inhibit the subsequent assembly of PBb,C3b in the absence of an
alternative pathway activator. The C3- and C5-cleaving enzymes
generated through either pathway, produce the inflammatory
fragments, C3a, C3b and C5a, and also lead to the generation of
the membrane attack assembly, C5b-9. From Mayer (21) with
permission.
polymeric agents. For example, microbial polysaccha-
rides can activate the alternative pathway, while saltlike
complexes of DNA and lysozyme activate via the
classical pathway (26). Of particular interest, lipopoly-
saccharide (LPS) activates complement (viathe alterna-
tive pathway), and also B-lymphocytes and macro-
phages, in an immunologically nonspecific fashion (see
below).
Another important aspect ofthe complement system
is that it is activated via an enzymatic cascade, with
proteolytic cleavage of precursor components yielding
enzymatically active fragments which, in turn, cleave
(and "activate") succeeding components. By virtue ofits
enzymatic nature, the overall reaction is, in effect,
amplified. In particular, generation ofthe intermediate,
C3b, constitutes a major amplifying step in the alterna-
tive pathway by acting through a positive feedback loop
(see Fig. 1).
Lymphokines and Monokines
A number of cell-derived mediators have also been
characterized in vitro. In some cases, these mediators
exist as preformed substances within the cell (e.g.,
histamine within mast cell granules) and are released
into the extracellular environment following an appro-
priate stimulus. In other cases, stimulation of the cell
leads first to mediator synthesis, then release (e.g.,
lymphokine production by lymphocytes). The number of
biologic activities generated by activated cells is very
large; a partial list is given in Table 1. The lymphokines,
which at first were thoughttobe released exclusivelyby
T-(thymus dependent) lymphocytes, are now known to
beproduced, in some cases, byB-(bone marrow-derived)
lymphocytes as well (e.g., migration inhibitory factor)
(27). Only some ofthese mediators have been character-
ized physicochemically as yet, and it is possible that, in
some instances, different biologic activities may in fact
represent different manifestations ofthe samemolecule.
Soluble mediators released by activated lymphoid
cells include Interleukin 1 (IL-1; also known as "lymph-
ocyte activatingfactor"), Interleukin 2 (IL-2; also known
as "T-cell growth factor"), "mitogenic factor," "macro-
phage activating factor" and chemotactic factors, which
act in concert to attract, then activate other leucocytes
in an immunologically nonspecific fashion. These media-
tors constitute an important amplifying mechanism
and, as in the case of the complement cascade, enable
the host to mount a sizeable inflammatory response
following arelativelytrivialbutimmunologically specific
initiating reaction. In classic studies by McCluskey et
al. (28) and later by Cohen et al. (29), immune cell
participation in delayed-type hypersensitivity reactions
was examined in recipients passively sensitized with
radiolabeled lymphocytes. These studies demonstrated
that virtually all lymphocytes present at the inflam-
matory site were in fact "nonimmune" (i.e., they were of
host origin). Presumably, such cells were recruited (and
activated) by amplifying mediators.
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Table 1. Representative cell-derived mediators.
Mediator Mediator class Cell source Biological action(s)
Interleukin 2, mitogenic factor, Lymphokines Lymphocyte Induce lymphocyte growth/proliferation and/or maturation
T-cell replacing factor
Chemotactic factors Lymphokines Lymphocyte Individual factors chemotactic for neutrophils, monocytes, eosino-
phils or basophils
Vascular permeability factor Lymphokine Lymphocyte Increases vascular permeability
Lymphotoxin Lymphokine Lymphocyte Cytotoxic for L-cells and selected tumor cells
Migration inhibitory factor Lymphokine Lymphocyte Immobilizes macrophages
Macrophage activating factor Lymphokine Lymphocyte Activates macrophages
Fibroblast activating factor Lymphokine/ Leukocyte Stimulates proliferation/activation of fibroblasts
monokine
Interleukin 1 (lymphocyte Monokine Macrophages/ Activates lymphocytes; stimulates IL-2 production; induces fibro-
activating factor) monocytes blast proliferation; causes fever
C3a,C5a Complement Macrophages/ Causes cellular release of histamine; C5a also chemotactic for
monocytes neutrophils
Histamine, serotonin Vasoactive Basophils, mast Increase vascular permeability; contract smooth muscle
amines cells, platelets
Platelet activating factor Phospholipid Macrophages, baso- Induces platelet aggregation and secretion of vasoactive amines;
(AGEPC) derivative phils, neutrophils also stimulates neutrophil aggregation and secretion
PGE2, PGF2a, thromboxane, Arachidonate Leukocytes Diverse (and even opposing) inflammatory effects, depending on the
prostacyclin derivatives mediator; PGE2 also acts as an immunomodulator
5-HETE, 12-HETE Arachidonate Leukocytes Chemotactic for neutr-ophils; induce neutrophil granule release
derivatives
Leukotrienes B4, C4, D4, E4 Arachidonate Leukocytes LTC4, LTD4, LTE4 contract smooth muscle and increase vascular
derivatives permeability; LTB4 is chemotactic for neutrophils
Superoxide anion, Oxygen-derived Macrophages, Cytotoxic for endothelial cells, tumor cells
hydrogen peroxide free radicals neutrophils
IL-1 is of particular interest since it provides one of
the macrophage-derived signals necessary for both the
induction as well as the expression of the immune
response. In addition, it also is required for T-cell
responses to mitogens, and its ability to greatly amplify
such responses constitutes the basis for the IL-1 assay
(30). Its role in the production of inflammatory lung
disease seems certain since alveolarmacrophages, when
activated, produce IL-1 in large amounts, and since IL-1
also appears to be identical to endogenous pyrogen (31).
In the case ofrabbit alveolar macrophage IL-1, we have
shown the production oftwo distinct species possessing
molecular weights of 14,400 and 11,600 daltons, and
isoelectric points of 4.6 and 7.4, respectively (32).
Recently, IL-1 hasalsobeenreported to causefibroblasts
toproliferate (33), and synovial cells to secrete collagen-
ase (34). Thus, this single mediator, produced by
alveolar macrophages, helps establish immunity to
antigenic substances, facilitates activation of cellular
immune effector systembyboth antigens and mitogens,
produces fever, and may lead to pulmonary fibrosis.
As in the complement system, in which component
proteins exist as inactive precursor forms and become
biologically active only following enzymatic cleavage,
cell-derived mediator synthesis and/or release typically
occurs only following activation of the cell by an
appropriate stimulus. This can occur in an immunologi-
cally specific fashion, as when antigen binds to recep-
tors on immune T-lymphocytes, or to antigen binding
sites of homocytotropic antibody on the surface of
basophils. It can also occur, however, as a consequence
of immunologically nonspecific cell activation by a
variety of agents termed "mitogens" or "polyclonal cell
activators" (35) (see discussion of activation systems).
Among the cell activators known to trigger lymphokine
and monokine production by lymphocytes and macro-
phages are plant lectins, microorganisms and their
constituents (including LPS), and certain chemicals and
enzymes (see Table 2). Polyclonal cell activators can also
trigger basophils to release vasoactive amines (36)
which, in turn, promote tissue inflammation by enhanc-
ing passage of other humoral and cellular effectors out
of the blood vessels and into the interstitial spaces.
Platelet-Activating Factor
IgE-coated basophils, when stimulated with specific
antigen, release not only vasoactive amines directly, but
also platelet-activating factor (PAF) which, in turn,
causes release of additional vasoactive amines from
platelets. PAF, a potent, biologically active lipid re-
cently identified as acetyl glyceryl ether phosphoryl-
choline (AGEPC) (37), is also released by stimulated
monocytes, neutrophils, mast cells and, of particular
relevance to this discussion, alveolar as well as perito-
neal macrophages (38). In vivo studies in experimental
animal models have shown that PAF, when injected
intravenously, causes depletion of circulating neutro-
phils, basophils and platelets, with pulmonary platelet
sequestration (39), increases vascularpermeability, pro-
motes immune complex deposition in serum sickness
(40) and causes bronchoconstriction (41). It has been
further suggested that variations in PAF release from
alveolar macrophages reflect different states of activa-
tion of these cells (38).
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Table 2. Polyclonal cell activators.
Hydroxy-
eicosatetraenoic
lipoxygenase Hydroperoxy- acids (HETE 's)
Plant lectins
Phytohemagglutinin (PHA)
Concanavalin A (Con A)
Pokeweed mitogen (PWM)
Peanut agglutinin
Soybean agglutinin
Walnut extracts
Corn extracts
Microbial organisms and their products
Gram negative endotoxin (LPS)
Staphylococcal A protein; enterotoxin B
Streptolysin S
Peptidoglyeans (E.,coli; B. megaterium)
Pneumococcal polysaccharide (SI,,)
Micropolyspora faeni
Herpes simplex
Epstein-Barr virus
Nocardia sp.
Endogenous cell-derived mediators
Mitogenic factor
Interleukin 1 (lymphocyte-activating factor)
Interleukin 2 (T-cell growth factor)
Macrophage-activating factor
Miscellaneous mitogens
Trypsin; papain
Neuraminidase/galactose oxidase
Sodium periodate
Phorbol esters
High molecular weight polymers (dextran sulfate; poly I-C; keyhole
limpet hemocyanin)
Calcium ionophores (A-23187)
Mercury; zinc; nickel
Anti-immunoglobulin antibodies
Arachidonic Acid Metabolites
A fourth major immune effector system consists of a
family of lipidlike mediators which are generated
through metabolism of arachidonic acid, derived from
membrane phospholipids by the actions of phospho-
lipases (42). These mediators, in turn, can be subdi-
vided into products of the cyclooxygenase pathway
(including prostaglandins, prostacyclin and thrombox-
anes), and those produced through the lipoxygenase
pathway (leukotrienes, including B4 and SRS-A;
HPETEs and HETEs) (Fig2). Both classes ofoxygena-
tion products are known to be synthesized in the lung,
primarily by alveolar macrophages (43).
The prostaglandins have been studied extensively in
vitro and in vivo, often by blocking their production by
aspirin andindomethacin, whichinhibit cyclooxygenase.
Potentially, they can function both as effectors and
regulators ofinflammation invivo, buttheir precise role
in tissue inflammation is somewhat difficult to define
since different products may have opposing biologic
activities. Moreover, they may be produced simultane-
ously, but in different quantities, and may have different
biologic half-lives. Nevertheless, the well-known anti-
inflammatory actions ofaspirin almost certainly results
from inhibition of cyclooxygenase activity in vivo.
Interestingly, the lung not only is an important site for
prostaglandin synthesis, it also is a major site for
inactivation of certain prostaglandins (44).
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FIGURE 2. Schematic representation of the cyclooxygenase and
lipoxygenase pathways of arachidonic acid metabolism.
Arachidonic oxygenation productsofthelipoxygenase
pathway, on the other hand, are relatively insensitive to
the action ofthe nonsteroidal anti-inflammatory drugs.
SRS-A("slow-reactingsubstanceofanaphylaxis"), which
is known to play a role in anaphylaxis, has been shown
to be leukotrienes C4 and D4 (45). The chemotactic and
degranulating properties of certain HETE molecules
(46) as well as leukotriene B4 suggestthatthey, too, may
play a role in immunologic lung disease.
Oxygen-Derived Free Radicals
Last, a fifth effector system has recently emerged
which may be important in parenchymal lung disease,
and which involves the extracellular release of oxygen-
derived free radicals, particularly H202, OH and 02-,
by stimulated neutrophils and macrophages. These
radicals are known to be important mediators of both
the intracellular killing ofphagocytized microorganisms
and, in some cases, the extracellular killing of tumor
cells by macrophages (47). They have been implicated in
both the direct cutaneous Arthus reaction (48) as well as
a reverse passive Arthus reaction produced in the lung
(49), since inflammation associated with these reactions
canbeblockedbyintroductionofenzymatic"scavengers"
capable ofrapidly inactivating oxygen free radicals. In
vitro studies by Jacob and co-workers (50) have demon-
strated that biologically active complement fragments
can cause neutrophils to release oxygen radicals into the
extracellular environment, and that these radicals dam-
age endothelial cells growing in culture. They have
proposed that such reactions may be responsible for the
acute respiratory distress syndrome in man. Unfor-
tunately, attempts to reproduce this disorder in an
animal model have been unsuccessful (51).
ActivationSystemsWhichInitiate
Parenchymal Lung Disease
The preceding section describes known effector sys-
tems capable ofmediating immunologic tissue injury. It
a eicosateraenoie _ I.
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should be emphasized, however, that these systems
exist in normal as well as diseased individuals, and are,
in fact, primarily protective forthe host (52). Whether a
particular system acts to benefit the host or, instead,
cause disease is determined by the conditions of
activation, especially the nature ofthe initiating signal,
as well as by the effectiveness of relevant control or
regulating mechanisms in modulating and, eventually,
terminating the effector system once activated.
Immunologically Specific Mechanisms
The "classical" means by which immune effector
systems are activated is through interaction of antigen
with specific antibody or sensitized lymphocytes. In the
case ofimmunologically mediated diseases, these inter-
actions can be further subdivided into (a) reactions
directed against antigens which are immunologically
unrelated to the target organ affected, and (b) reactions
directed against one or more antigens intrinsic to the
organ structure. Examples ofthe first case include lung
injuryassociatedwithcirculatingantigen-antibody com-
plexes arriving via the circulation which become local-
ized or "trapped" in the lung, or by complexes forming
in situ between inhaled antigens and circulating (or
locally synthesized) antibody An example ofthe second
case is the formation of autoantibodies, specific for
capillary basement membrane antigens, and which,
when they bind in vivo, cause pulmonary hemorrhage
and glomerulonephritis (Goodpasture's syndrome).
While sometimes described as an example of a "cyto-
toxic" mechanism (53), such injury in fact appears to
result from damage to the extracellular basement
membrane, presumably through local release ofproteo-
lytic enzymes (54) and, possibly, oxygen radicals.
Antigens can also activate immune lymphocytes,
eitherby binding to cell membrane antibody (B-cells) or
byinteractingwith immunologically specific T-cell mem-
brane receptors. B-cell activation typically leads to
B-cell proliferation and differentiation, accompanied by
synthesis and release of specific antibody and certain
lymphokines as well (27). Stimulation of T-cells results
in lymphokine release, cell proliferation and differen-
tiation. While antibody production per se does not
necessarily result in tissue inflammation, local release
of lymphokines probably does.
Immunologically Nonspecific Mechanisms
Yet another means by which immune effector systems
can be activated is through the actions ofmitogens, also
known as "polyclonal cell activators," which activate
nonimmunelymphocytes, macrophages, basophils, mast
cells and complement in an immunologically nonspecific
fashion (35,55). Best studied of these mitogens are the
plant lectins, phytohemagglutinin (PHA) and con-
canavalin A (Con A), which bind to specific sugar
moieties or"receptors" on cell surfaces. When they bind
to T-lymphocytes, they further initiate a sequence of
biochemical and morphological events which transform
the cell from a "resting" state to an "activated" one in
whichthecellsincreaseinsize, synthesizenewenzymes,
produceandsecretelymphokines, undergoblastogenesis
and cell division and, ultimately, acquire differentiated
cell functions such as cytotoxic capabilities (35). Since
these effects parallel those induced in "immune" T-cells
by specific antigen, these lectins came to be widely used
for in vitro studies of cell-mediated immunity. In this
regard, they offered notable advantages over the use of
antigen in that: they were effective on cells from
"immunologically-naive" (i.e., notpreviouslyimmunized)
donors; byactingonlymphocytes in apolyclonal fashion,
they activated larger numbers oflymphocytes than did
specific antigen, thereby exaggerating the in vitro
responses; and mitogens were useful in defining subsets
of lymphocytes, based on their ability or failure to
respond to a particular mitogen.
Subsequently, T-cell mitogens have been used to
simulate cell-mediated or delayed-type hypersensitivity
reaction in vivo as well, first in the skin, and subse-
quently in the lung and other organs (56,57). However,
as yet little consideration has been given to the possible
role ofmitogens per se as a cause ofenvironmental lung
disease in man, although experimental studies have
clearly demonstrated that mitogens are capable of
causing a rapidly developing pneumonitis by them-
selves and, under certain circumstances, triggering
immune complex reactions leading to pulmonary fibro-
sis. (57). Moreover, the list ofknown mitogens presently
includes viruses, bacteria (and LPS), thermophilic
Micropolyspora, enzymes and chemicals (Table 2), many
of which are known to cause human disease; it is
apparent that they may do so partly through their
ability to activate nonimmune lymphocytes in a poly-
clonal fashion. Moreover, it is further possible that
patients predisposed to inflammatory lung disease may
be unable to regulate responses to local mitogenic
stimulation in a proper fashion.
The association between a1-antiprotease deficiencies
and apropensitytoinflammatorylungdisease (including
fibrosing alveolitis) is well known. It is particularly
interesting, then, to note that a1-antiprotease has been
shown to inhibit lymphocyte activation by T-cell mito-
gens (58,59). We have extended these observations by
showing that a1-antiprotease inhibits IL-1 activity, in-
cluding both its T-cell activatingproperties as well as its
ability to stimulate fibroblast proliferation (60,61). In
addition, certain proteases (including trypsin), which
are inhibited by a1-antiprotease, are known to be B-cell
mitogens (35). Thus, it seems highly plausible that
al-antiprotease may not only act by inhibiting proteo-
lytic degradation of lung tissue at the site of an
established inflammatory reaction, as has been pro-
posed (62), but may also regulate the very initiation of
such inflammation as well.
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Experimental Animal Models of
Immunologic Injury to Lung
Parenchyma
Arthus-Type Injury
Experimentally induced, immunologically mediated
lung injury was first observed nearly a century ago
when it was demonstrated that immunized guinea pigs
challenged with antigen administered via the airways
went into anaphylactic shock (63). The first Arthus-type
pulmonary lesions were reported by Opie (64), who
stated that injection of horse serum through the tho-
racic wall of an immune rabbit caused local consolida-
tion with a central zone of necrosis. Subsequently, a
number of investigators have employed such direct
active Arthus models, or in some cases, a reverse
passive Arthus approach, in which animals are first
injected with antigen intravenously, then challenged
with intratracheal injections of antibody, resulting in
acute, neutrophil enriched intra-alveolar hemorrhages
(65).
Circulating Immune Complex Injury
Another experimental approach to studying experi-
mental immunologic lung disease has employed a serum
sickness model, characterized by sequestration of
circulating immune complexes within the lung. Vaubel
(66) first described hyalin capillary "thrombi" in lungs of
rabbits dying in anaphylactic shock following intrave-
nous injections of serum protein antigen, while Gregory
and Rich described similarlesions inrabbits undergoing
chronic serum sickness (67). Subsequently, Dixon (68)
and McKinnon et al. (69) demonstrated that such lesions
in fact represented intravascular precipitates ofantigen
and antibody. Recently, Brenjens et al. (70) extended
the chronic serum sickness model to show that, in
rabbits making hyperactive antibody responses to daily
injections of bovine serum albumin (BSA), immune
complexes would deposit along the alveolar capillary
walls and interstitium, accompanied by interstitial
inflammation and basement membrane thickening. This
finding was particularly interesting, since it is well
knownthatpatientswithimmune complex-type diseases,
such as rheumatoid arthritis and systemic lupus ery-
thematosus, have an increased likelihood of developing
interstitial pulmonary fibrosis (13). As mentioned
previously, circulating immune complexes have also
beendemonstrated inpatients with"idiopathic" intersti-
tial pulmonary inflammation, in the absence of other
manifestations of a connective tissue disorder (13).
Autoimmune Injury
Experimental studies using animals models have also
clarified mechanisms of lung injury initiated by anti-
lung antibody. First, it was demonstrated that the lung
shares antigenic determinants with other highly vascu-
lar structures such as the renal glomerulus, placenta,
liver and spleen (71). Antisera against such organs
cross-reactextensively, althoughsomelung-specificanti-
body can be demonstrated. A particularly elegant
demonstration of such specificity was provided by
Pressman (72), who developed a paired-isotope method
for quantitating small amounts of antibody localization
in vivo. In this technique, antibody-containing immuno-
globulin is radiolabeled with 1 5I, while a control
(nonantibody-containing) immunoglobulin preparation
is labeled with 131I, and mixtures of the two labeled
preparations injected intravenously. Although all or-
gans will contain both 131I as well as 125I, bound to
immunoglobulin molecules present in the vascular com-
partment and within the interstitial spaces, tissues
containingspecificallyboundantibodywillhavea1251/131I
ratio somewhat greater than that ofthe blood; it is then
possible, by means of simple calculations to determine
net increase in 125I present and, hence, the net amount
of antibody fixed.
The ability of heterologous anti-lung antibody to
cause lung injury has been convincingly demonstrated
in several laboratories where, in every case, such injury
was characterized by intraalveolar hemorrhage, to-
gether with acute glomerulonephritis and proteinuria
(73,74). Whereas most studies employed antisera pre-
pared against whole lung homogenate, Willoughby and
Dixon (74) prepared rabbit antibody against partially
purified rat pulmonary vascular basement membrane
antigen. After isolating the antibody-containing IgG
fraction by column chromatography, they radiolabeled it
with 125I, and injected it (together with 131I-labeled
normal IgG) intravenously into rats. Thus, by using the
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FIGURE 3. Paired-isotope measurements ofrabbit anti-rat lunganti-
body (Ra PTAB) binding in vivo following intravenous injection
into Sprague-Dawley rats. Each point represents the average
value obtained with six rats. Threshold values (broken horizontal
lines) give minimal injected dose/organ fixation required for
pulmonary hemorrhage and protein-uria From Willoughby and
Dixon (74) with permission.
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paired-isotope technique, they were able to observe the
dose-response relationships between antibody binding
in the lung and kidney, and the development of pulmo-
nary hemorrhage and glomerulonephritis, respectively
(Fig. 3). Simultaneously, immunohistochemical staining
demonstrated the anatomic sites of antibody binding
(alveolar capillary membranes, glomerular basement
membranesandliverandspleenreticulum). Surprisingly,
only relatively small amounts of antibody bound to the
alveolar capillaries in these animals, doing so in a very
focal fashion; instead, most ofthe antibody bound to the
glomerular basement membrane and hepatic and sple-
nic reticulum (74). Ultrastructural studies have sug-
gested that the alveolar capillary basement membrane
is shielded by a continuous layer of endothelium (in
contrast to the glomerular basement membrane, he-
patic and splenic reticulum, where basement mem-
branelike antigens come into direct contact with the
circulation through "gaps" in the endothelial cell layer)
(75). Thus, Willoughby and Dixon suggested that per-
haps it was necessary for a localized insult or lesion to
occur before circulating antibody could bind to alveolar
basement membrane antigens (74). Recently, Jennings
et al. (76) have provided direct experimental con-
firmation of this concept by showing that oxygen-
induced injury to alveolar capillary endothelium greatly
enhanced binding of circulating anti-basement mem-
brane antibody, and thereby increased the severity of
pulmonary injury. All of these animal models closely
resemble Goodpasture's syndrome in man, in which
pulmonary hemorrhage and glomerulonephritis occurin
association with circulating autoantibodies to basement
membrane (77).
At present, it is not known why autoantibodies to
alveolar capillary basement membrane are produced
nor, for that matter, what events might trigger acute
hemorrhagic episodes in patients with Goodpasture's
syndrome. In some cases, there is a history ofexposure
to hydrocarbon solvents (78). In this regard, the sera of
normal animals have been demonstrated to contain
antigenic fragments of alveolar capillary basement
membrane which appear immunologically indistinguish-
able from those excreted into the urine (74). When such
urinary antigens are emulsified in Freund's adjuvant
and injected back into the host, autoantibody formation
occurs (79). Thus, itispossible thatinhaled environmen-
tal agents might increase release ofantigenic fragments
into the circulation, alter them chemically, or both,
thereby prompting an autoimmune response by the
host. Such an agent might also cause focal increases in
alveolarcapillarypermeability, therebyfacilitatingbind-
ing of circulating antibody to the capillary basement
membrane. On the other hand, recent experimental
studies by Izui, Moller, and Coutinho (80) have provided
provocative evidence indicating that autoantibody pro-
duction may be the result of polyclonal activation
induced by mitogens acting nonspecifically on T-and/or
B-cells.
Evidence for cell-mediated immune injury to lung
tissue has been most clearly demonstrated in studies of
pulmonary allograft rejection. In one such study, Lee et
al. (81) performed heterotopic heart/lungallografts using
inbred rat strains, thereby permitting the use of
isograft controls. These investigators demonstrated
that early cell-mediated injury to lung allografts, seen
at 2 days post-transplant, consisted of perivascular
mononuclear infiltrates affecting small and medium-
sized pulmonary arteries. Later changes, observed 2
weeks post-transplant, consisted of occlusive endothe-
lial proliferation, perivascular fibrosis and diffuse mono-
nuclear infiltrates throughout the pulmonary paren-
chyma.
Immunologic Injury Induced by
Inhaled Substances
Whereas the preceding models of pulmonary injury
caused by circulating immune complexes or autoim-
mune reactions constitute mechanisms capable ofaffect-
ing most organs, the unique anatomic relationships of
the lung render it vulnerable, in theory, to yet another
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FIGURE 4. Total body uptake of inhaled "25I-labeled bovine serum
albumin (BSA), expressed as a function of total 125I-BSA
aerosolized. 125I-BSA was administered daily (100mg/day) for 1, 3
or 5 consecutive days to 11, 11, and 10 rabbits, respectively.
Rabbits were sacrificed 24 hr after the final dose. Ibtal uptake
values were calculated individually by summing radioactivity
measurements of organs, plasma, and cumulative urinary excre-
tions, then averaged for each group. Results are expressed as mg
equivalents of 12"I-BSA recovered. Vertical bars represent stan-
dard errors of the mean. From Willoughby and Willoughby (82).
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mechanism ofparenchymal injury; namely, hostimmune
reactions directed against inhaled substances. As noted
previously, such a hypothesis has been proposed to
describe the pathogenesis of allergic alveolitis. Conse-
quently, there have been numerous attempts to develop
an appropriate animal model for such injury in an effort
to identify possible pathogenic mechanisms. Obviously,
an ideal model would employ well-characterized, immu-
nologically defined agents, administered inaerosol form,
and would be characterized by the production of a
granulomatous interstitial pneumonitis (7). In practice,
most models employed to date represent compromises
of one or more of these goals. Thus, a variety of
antigens, including bovine serum albumin (BSA) (82),
azobenzenearsonate (83), ovalbumin (84), PPD (85), M.
faeni (86,87), pigeon droppings (88), and heterologous
serum (89) have been used. Antigen challenge has been
administered by aerosol inhalation (82,84,90), direct
intrapulmonary instillation (65), or even transtracheal
injection (86), resulting in injury patterns ranging from
pulmonary consolidation (63) to a neutrophil-rich intra-
alveolar hemorrhage (65), to no injury at all (82).
No general agreement has been reached concerning
the mechanism(s) involved. Fried (63) originally sug-
gested that injury produced by intratracheal injections
of horse serum into immunized rabbits resembled the
cutaneous Arthus reaction. Hensley and Fink (89)
obtained support for this concept by demonstrating
antigen, host immunoglobulin and complement (C3) by
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immunofluorescence staining in lung tissues from
monkeys sensitized passively with antibody, then chal-
lenged with antigen aerosol; similar findings were
observed by Santives et al. (91) in the guinea pig. By
prior decomplementation with cobra venom factor,
Roska et al. (92) were able to prevent injury in
ovalbumin-immunized guinea pigs challenged with
ovalbumin aerosols. Johnson and Ward (65) also demon-
strated a requirement for complement and neutrophils
in the reverse passive Arthus model, and further
suggested a role for oxygen-derived free radicals in the
production of such injury (49).
In contrast, other investigators have failed to detect
evidence of immune complex injury in lungs of immu-
nized rabbits challenged with M.faeni (93) or BSA (82).
Thft et al. (94) were unable to prevent injury induced by
BSA aerosols in sensitized rabbits by prior de-comple-
mentation, while Moore et al. (88) actually observed
an inverse relationship between complement consump-
tion and injury following challenge with a pigeon
dropping extract. In one study, Santives et al (91)
reported that IgE antibody serves to trigger immune
complex disease; however, most studies to date have
failed to demonstrate a role for homocytotropic anti-
body in these models (87,88,92). In retrospect, convinc-
ing models ofinhalation-induced, immune complex-type
lung injury have been demonstrated primarily in con-
junction with selected "enhancing" measures, including
simultaneous mitogen inhalation (57,90), intramuscular
HOURS
FIGURE 5. Distribution ofproteinlabel as afunction oftimefollowing asingle aerosol administration of '25I-BSA. Values are expressed as mean
percentage oftotal in vivo label recovered in organs, plasma and cumulative urine in individual rabbits. Organ values were calculated by the
paired isotope technique. The insert gives values for three individual organs. Vertical bars give the range ofexperimental values observed.
From Willoughby and Willoughby (82).
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injections of complete Freund's adjuvant (91), or intra-
vascular injections of killed BCG organisms (88). The
latter two approaches, while effective, may be of
questionable relevance to human disease; the potential
role of inhaled mitogens, on the other hand, may be
particularly relevant.
The ability ofhumoral antibody or sensitized lympho-
cytes to passively sensitize test animals to subsequent
injury by aerosol challenge has been studied in several
laboratories. Adoptive sensitization using serum anti-
body has been achieved successfully in some instances
(89,95), but not others (94,96). Transfer of sensitized
cells has been reported to render the guinea pig
susceptible to inhalation injury (97); Wilkie et al. (87)
found that either cells or serum worked satisfactorily.
Bice et al. (98) were able to adoptively sensitize rabbits
tosubsequent aerosolchallenge bygivingintraperitoneal
injections of allogeneic lymphoid cells (but not serum)
obtained from immunized donors. Other cell-transfer
techniques, carried out in outbred animals, have experi-
FIGURE 6. Pulmonary histopathology in a BSA-immunized rabbit
challenged with BSA aerosol. The small, solitary focus of
granulomatous, interstitial inflammation, seen in the lower left, is
characteristic of the widely scattered, almost trivial lesions
occasionally present in rabbits immunized with BSA in alum
depots, and challenged for three consecutive days with BSA
aerosols, 100 mg BSA/day (estimated total pulmonary uptake is
480 ,ug BSA). H&E; x60.
enced technical difficulties due apparently to histocom-
patibility differences between donor and recipient or to
rapid antibody production by the transferred cells (89).
Willoughby and co-workers, in developing an animal
model ofenvironmental lung disease, have employed an
aerosol challenge system in which antigens and mito-
gens can be administered to (and inhaled by) rabbits
under precisely defined conditions (82). The uptake,
organ distribution and fate ofthese proteins in vivo has
been quantitatively determined by radiolabeling pro-
cedures, while their anatomic localization within the
lung has been observed directly by labeling them with
fluorescein. Under the standardized conditions em-
ployed, one can estimate the total body uptake of
inhaled protein as a function of the amount nebulized
(Fig. 4). Using a modification of the paired isotope
system to correct for plasma label, they have measured
the organ sequestration ofinhaled protein as a function
oftime following aerosol administration (Fig. 5). While
at least 10% of the inhaled protein initially reaches the
lung, mostis eventually cleared into the gastrointestinal
tract and digested. The degraded peptides (which no
longer react with anti-BSA antibody) are absorbed into
FIGURE 7. Interstitial pulmonary inflammation induced by three
daily administrations ofCon A aerosol (estimated total pulmonary
uptake is 480 ,g ConA). H&E; x 110.
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the circulation, where they reach maximal concentra-
tions at 24 hr post-aerosol (82). By 48 hr post-aerosol,
all protein has been degraded, and the radiolabel
excreted into the urine. The presence ofhost immunity
to the inhaled protein does not significantly affect the
fate of this protein in vivo (82). The fate of intrapul-
monary antigen is critically dependent on the experi-
mental conditions under which it is introduced, however
(99). For example, direct instillation of antigen-con-
taining solutions into the lung (82,100)-or insufflation
of antigen aerosols into extirpated perfused lungs
(101)-results in release of intact antigen into the
circulation, due possibly to alterations in tightjunctions
of cellular barriers (102).
Using this defined aerosol administration system, it
was next demonstrated that administration of antigen
(BSA) aerosols to immunized rabbits (possessing circu-
lating antibody to BSA following repeated intramuscu-
lar injections of BSA in alum) induced only minimal
pulmonary inflammation (Fig. 6); no injury was ob-
served in previously unimmunized recipients, even
following repeated (biweekly) aerosol challenges which,
bythemselves, eventuallyinduced hightitersofcirculat-
ing anti-BSA antibody (1 mg/mL) after several weeks
(82).
In contrast, administration ofT-cell mitogens (Con A
or PHA) in aerosol form induces a diffuse interstitial
pneumonitis characterized by interstitial edema and
mixed inflammatory infiltrates in alveolar septa (Fig. 7)
(56,57,90). Immunohistochemical staining has revealed
numerous T-lymphocytes in such infiltrates (90), while
lavage fluids from Con A-treated animals contained
significantly increased numbers of T-lymphocytes over
those present in saline controls (103), suggesting an
amplifying process characterized by T-cell proliferation
and/orrecruitment intothelung. Mitogen-induced inter-
stitial inflammation is reversible, and the lung lesions
resolve completely within several days following cessa-
tion of aerosol challenge (57).
Whereas antigen or mitogen aerosols, given indi-
vidually, produce trivial or moderate interstitial inflam-
mation, respectively, inhalation of antigen/T-cell mito-
gen mixtures by immune animals results in devastating
pulmonary inflammation with areas of parenchymal
necrosis and even infarction (57,90,104) (Fig. 8).
Occasionally, these are severe enough to cause death
within hours of aerosol administration. These pulmo-
nary lesions are characterized by interstitial edema and
inflammatory infiltrates of neutrophils, lymphocytes,
macrophagesandbasophils. Immunofluoresence micros-
copy has demonstrated inhaled antigen, specific anti-
body and C3 as granular interstitial deposits (Fig. 9), at
or near necrotic foci in the lung; such deposits were not
observed in animals challenged with antigen ormitogen
alone (57,82,104). Repetitive weekly challenges with
antigen/ mitogen aerosols produce chronic pulmonary
injury characterized by areas of focal scarring and
interstitial fibrosis (57) (Fig. 10).
~~~ r~~~~~~Vr
FIGURE 8. Parenchymal necrosis and bland infarction ofpulmonary
tissue following administration ofthree consecutive daily aerosols
ofBSA and Con A to BSA-immunized rabbits. Note the small rim
of viable lung tissue on the left showing only interstitial
inflammation. (H&E; x45).
These observations thus demonstrate two pathogenic
effects of these phytomitogens. First, they induce
interstitial pulmonary inflammation when inhaled, even
in anunimmunized host. Second, theytrigger formation
of pathogenic immune complexes between inhaled
antigen, humoral antibody and complement. Since Con
A is known to activate T-lymphoctes (and, in some
instances, basophils as well) in a polyclonal fashion in
vitro, we have proposed that its unusual toxicity for the
lung results from its ability to activate these cells in
vivo, again in an amplified, polyclonal fashion (90).
We further suggest that, whereas under usual circum-
stances inhaled antigen normally does not come into
direct contact with humoral antibody, probably because
the type I pneumocytes serve as an effective anatomic
barrier (Fig. lla), mediators released by mitogen-
stimulated lung lymphocytes and macrophages may
alter or disrupt this barrier (Fig. llb), thereby enhanc-
ing interactions between intra-alveolar antigen and
interstitial/intravascular antibody (Fig. 1hc). Formation
of immune complexes, accompanied by complement
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FIGURE 9. Immunofluorescence microscopy. (a) Localization ofinhaled BSA inthe lungofaBSA-immunized rabbitchallenged with BSA-ConA
aerosol. Note the massive deposits ofBSA inmarkedly thickened septa(lowerleft) as compared to the delicate depositsalongouter surface of
septa (top) which are relatively norrnal in thickness; x300. (b) Demonstration of rabbit IgG in a BSA-immunized rabbit challenged with
BSA-Con A aerosol. Note the granular pattern of localization within the thickened septa; x300. From Willoughby et al. (57).
activation, then results in chemotactic attraction of
neutrophils into the interstitial spaces (57) where,
through release of proteolytic enzymes and, possibly,
oxygen radicals, the collagen and elastin structural
framework is destroyed, resulting in necrosis or dissolu-
tion of tissue structure.
To test the hypothesis that inhaled mitogens initiate
or "trigger" immune complex formation between in-
haled antigen and circulating antibody, Shenker et al.
(104,105) blocked the responsiveness oflymphocytes to
T-cell mitogens in vivo by parenteral administration of
cholera toxin. Such treatment elevated the cAMP levels
of peripheral blood lymphocytes and blocked their
proliferative responses to subsequent stimulation by
Con A in vitro. It also inhibited the tuberculinlike
response to intradermal injections ofCon A, but did not
affect the immune complex-mediated cutaneous Arthus
vasculitis (104,105), thereby demonstrating a selective
inhibition of cell-mediated reactions. If immune com-
plex formation in the lung is dependent upon initiation
by mitogen-activated leukocytes, it may be predicted
that cholera toxin should inhibit both the mitogen-
induced interstitial inflammation and immune complex-
mediated parenchymal necrosis. The hypothesis was
supported by the experimental data; both forms of
pulmonary inflammation were prevented by cholera
toxin administration (104,105). Not only did these
experiments provide critical support for the role of
mitogens in "triggering" immune complex formation in
the lung, they further suggested that individual suscep-
tibility to environmental lung disease may depend, in
part, on the inherent responsiveness of an individual's
leukocytes to mitogen activation (104).
This conceptual argument was further strengthened
by Hollingdale et al. (104,106), who showed that
decomplementation with purified cobra venom factor
(CVF) [which lowered serum complement (CH50) hemo-
lytic titers by 80% and lowered C3 concentrations by
82%] markedly inhibited the cutaneous Arthus vasculi-
tis without affecting the cutaneous inflammatory re-
sponse to Con A. As expected, CVF also prevented the
production of immune complex-mediated parenchymal
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FIGURE 10. Pulmonary fibrosis induced by thrice weekly challenges
with BSA-Con A aerosol for 8 weeks. Note scattered round cell
infiltrates and distorted residual air spaces. x 110. Willoughby et
al. (57).
necrosis by antigen/mitogen aerosols, but did not pre-
vent the interstitial inflammation characteristic of in-
jury induced by inhaled mitogen alone.
Recently, we have begun a study of the pathogenic
actions ofinhaled B-cell mitogens, comparingthem with
those previously described for T-cell mitogens. Such
studies are deemed particularly appropriate, since M.
faeni has been shown to be a B-cell mitogen (107), while
another B-cell mitogen, bacterial lipopolysaccharide
(LPS), is thought by some to represent the pathogenic
agent in cotton dust causing byssinosis (108). A variety
of types of LPS, derived from different organisms and
extracted by either the Westphal or butanol methods,
have been found to induce a diffuse interstitial pneu-
monitis (Fig. 12). Dose-response studies have indicated
that inhalation ofapproximately 100 pug of LPS into the
lung for each of three consecutive days results in a
severe interstitial inflammation, while inhalation of
lesser amounts (10-33 ,ug) results in little or no
inflammation. Moreover, inhalation of LPS also results
in a slightly delayed febrile response, generally reach-
ing a maximal value 2-4 hr post aerosol (103). Of
particular interest, however, is our preliminary finding
that LPS does not triggerimmune complex injury when
administered in conjunction with specific antigen to
immunized animals, even though it produces an intersti-
tial pneumonitis fully as severe as that produced by Con
A. Thus, initiation of pulmonary immune complex
formation by Con A must not represent merely the
effects of a nonspecific injury to the alveolar inter-
stitium, but instead must result from some relatively
specific property of this lectin in the lung. An obvious
possibility is that it may activate intrapulmonary T-cells
to release vascular permeability factor (109), or mast
cells and basophils to release vasoactive amines (36),
thereby increasing vascular permeability. Alternatively,
it may serve as a particularly effective stimulus for local
generationofAGEPC orofoxygen-derivedfreeradicals.
Regardless ofthe exact effector system(s) involved, the
important point is that, while all polyclonal cell activa-
tors which we have tested to date are capable ofcausing
pulmonary interstitial inflammation, some, but not all,
also act to trigger local immune complex formation
under the appropriate circumstances.
In order to determine whether mitogen-induced
lung injury is mediated through release of soluble
mediators by mitogen-activated cells, it is first neces-
sary to characterize such mediators in vitro, in order to
facilitate their subsequent identification in broncho-
pulmonary lavage fluids. As a first step, we have
generated and characterized two rabbit lymphokines,
lymphotoxin (LT) and mitogenic factor (MF), together
with a monokine, IL-1. [MF appears to be identical to
Interleukin 2(IL-2).] These mediators were selected in
part because they can be readilymeasured in aquantita-
tive and reproducible fashion. In addition, MF repre-
sents an endogenous mitogen thought to play an impor-
tant role in the amplification of host immune effector
responses (110), while IL-1 is generally believed to serve
as a central mediator in the acquisition and expression
of cellular immune effector systems and, in particular,
exerts an important (and, possibly, critical) role in
cellular responses to exogenous mitogens (32). The
physicochemical properties of these rabbit mediators
are given in Table 3.
Recently, we have found both IL-1 as well as a LT-like
factor in lavage fluid from animals challenged with LPS
aerosols (103). Thus, we suggest that IL-1 can be
released in vivo following activation of alveolar macro-
phages by inhaled mitogen, and that IL-1 so released
plays a central role in the production offever, interstitial
inflammation and even the "adjuvant" effects associated
with allergic alveolitis in man. Recently, it has been
shown that B-cells from such patients are more respon-
sive to stimulation by IL-1 than are cells from control
cohorts (9).
If polyclonal activation of pulmonary leukocytes by
inhaled mitogens is indeed relevant to human environ-
mental lung disease, than at lease some environmental
dusts known to cause lung disease should, in turn,
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FIGURE 11. A hypothetical model describing parenchymal lung injury by inhaled antigens and mitogens: (a) above; (b,c) facing page. (a)
Inhalation of antigen alone by immune individuals. Antigen molecules (open circles) within alveolar air sacs do not come into contact with
antibody molecules ("Y"-shaped figures) present within the capillaries and interstitial spaces. Although some T-lymphocytes are present in
the air spaces, the number which are specifically immune to any particular antigen is negligible, and cell-mediated immune reactions are not
initiated. (b) In contrast, inhaled mitogens (closed circles) can activate lymphocytes in a polyclonal fashion, thus resulting in asignificant local
inflammatory response. Direct activation ofintrapulmonary lymphocytes and, in some cases, ofalveolar macrophages as well, results in local
mediator release which further amplifies the local inflammatory process, and may also alter tight cellular junctions between Type I
pneumocytes and possibly endothelial cell junctions in addition. Although accessibility of intraalveolar substances to circulating antibody is
now greatly enhanced, no immune complexes form in the absence ofinhaled antigen. (c) When immune individuals inhale mixtures ofantigen
and mitogen (or when the dust particles possess both antigenic and mitogenic properties), leukocytes are first activated to release mediators
which, in turn, promote formation of immune complexes between intraalveolar antigen and circulating antibody Complement is then
activated, leading to neutrophil recruitment, lysosomal enzyme release and oxygen-derived free-radical generation. Necrotizing injury and
subsequent fibrosis results from enzymatic destruction of the collagen, basement membrane and elastin framework of the pulmonary
interstitium. (Abbreviations: VPF, vascular permeability factor; LT, lymphotoxin; CF, lymphocyte-derived chemotactic factor; MAF,
macrophage-activating factor; MIF, macrophage migration inhibitory factor; LAF, lymphocyte activating factor, also known as IL-1; EP
endogenous pyrogen, now thought to be identical to LAF; AGEPC, acetyl glyceryl ether phosphorylcholine, the chemical name for platelet
activating factor).
possess polyclonal cell-activating properties. Studies
from our laboratory and from Burrell's laboratory (107)
have shown that the causative agent for farmer's lung,
M. faeni, is mitogenic for B-lymphocytes from immuno-
logically naive or even germ-free animals (103) and that
it also stimulates macrophages to release IL-1 (103).
Moreover, M. faeni skin tests are known to be of little
value, since they often give "false positive" reactions in
nonimmune individuals (7) (as do Con A and PHA).
Thus, this organism may indeed be actingas apolyclonal
activator in man. In a rather different pulmonary
disorder, byssinosis, respiratory symptoms are caused
by an agent in respirable cotton dust which is thought
by some to be LPS (108), a known B-cell mitogen and
macrophage activator (35).
Since there are many different organic and inorganic
substances present inthe environment which are known
to be mitogenic (Table 2), the potential role ofpolyclonal
cell activation as a cause ofenvironmental lung disease
deserves serious consideration. Far from simply being
"toxic" agents which cause "nonspecific" injury, they
activate cells by binding to specific receptors; thus,
their apparent lack of specificity, as compared to anti-
genic stimulation, simply reflects the widespread distri-
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FIGURE 12. Interstitial pulmonary inflammation induced in rabbits
by three daily aerosol administrations of LPS aerosol. The
estimated total pulmonary uptake is 150 jig LPS. H&E; x 110.
bution of mitogen receptors on cell surfaces (35).
Moreover, theyactivatepreciselythe sameinflammatory
effector systems as immunologically specific reactions,
and thus will closely resemble immunologic injury,
except that there will be no obvious relationship be-
tween the presence or absence ofdisease and true host
* ~ ~ ~ ~ ~ ~ ~ ~ ~ V
immunit;y per se.
Epilogue
Recent scientific advances in understanding the
inflammatory response, both at the biochemical as well
as cell-biology level, have presaged comparable ad-
vances in our understanding of pulmonary injury. The
multitude, of effector mechanisms which have been
identified and defined to date demonstrate elements of
complexity and redundance in the inflammatory re-
sponse, including highly effective amplification and
control systems. To attempt to relate a given disease to
the action ofasingle effectorsystem maywellrepresent
an over-simplification. However, it may be entirely
feasible to search for, and identify, a single initiating
event or process in a disease state. Indeed, many forms
Table 3. Physicochemical parameters of
rabbit-derived soluble mediators.
Molecular
pI S20,w D20,w El weighta
Lymphotoxin 5.1 3.76 7.37 0.72 44,000
Mitogenic factor 2.13 9.63 0.72 19,000
Interleukin-1
4.6 IL-1 4.6 2.0 12.5 0.73 14,400
7.4 IL-1 7.4 1.8 14.0 0.73 11,600
a Molecular weights calculated by the Svedberg equation.
of environmental lung disease can be viewed as the
consequence of an inappropriate activation of normal
inflammatory effector mechanisms. Atthe same time, it
is well known that attempts to control inflammatory
diseases byblockingone ormore ofthe effector systems
frequently extract a price of their own, such as in-
creased susceptibility to infection.
Antigen inhalation almost certainly occurs in an
ongoing fashion; it probably constitutes a major means
for establishing "natural" host immunity, and only
infrequently is associated with inflammatory lung
disease. Thus, the antigenicity ofan inhalant should not
imply that it will necessarily cause pulmonary injury,
nor, for that matter, should the presence of host
immunity to that inhalant. Recognition that inhaled
environmental substances possess mitogenic or poly-
clonal leukocyte-activating properties, on the other
hand, should be a cause for concern. If, indeed, the in
vivo pathogenicity of environmental mitogens parallels
their in vitro activating properties, as is the case with
Con A and LPS, then it should be possible to screen
environmental dusts formitogenic activity as a measure
of their disease-causing potential. At the same time,
one might be able to also screen inhabitants of that
environment for disease susceptibility, by determining
the responsiveness of their leukocytes to mitogenic
stimulation in vitro, using appropriate dust mitogens.
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